[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity
Christopher Peetz, Mirum Pharmaceuticals CEO and director, reported related transactions on 08/11/2025 executed pursuant to a Rule 10b5-1 plan. He exercised 40,000 employee stock options with an exercise price of $2.936, resulting in an increase in directly held common stock to 178,641 shares. On the same date he sold 40,000 common shares at $62.00, reducing his direct holdings to 138,641 shares.
The filing also shows indirect beneficial ownership of 208,570 shares held by The Peetz Family Trust and that the exercised options are fully vested. All reported transactions were made under a 10b5-1 written plan adopted November 22, 2024.
Christopher Peetz, CEO e membro del consiglio di Mirum Pharmaceuticals, ha segnalato operazioni correlate in data 08/11/2025 eseguite ai sensi di un piano Rule 10b5-1. Ha esercitato 40,000 opzioni azionarie per dipendenti con prezzo di esercizio di $2.936, portando la sua partecipazione diretta in azioni ordinarie a 178,641 azioni. Nella stessa data ha venduto 40,000 azioni ordinarie a $62.00, riducendo la sua detenzione diretta a 138,641 azioni.
Il deposito indica inoltre una detenzione beneficiaria indiretta di 208,570 azioni tramite The Peetz Family Trust e specifica che le opzioni esercitate sono pienamente vestite. Tutte le operazioni segnalate sono state effettuate nell'ambito di un piano scritto 10b5-1 adottato il 22 novembre 2024.
Christopher Peetz, CEO y director de Mirum Pharmaceuticals, inform贸 transacciones relacionadas el 08/11/2025 ejecutadas conforme a un plan Rule 10b5-1. Ejerci贸 40,000 opciones sobre acciones para empleados con un precio de ejercicio de $2.936, lo que elev贸 su participaci贸n directa en acciones ordinarias a 178,641 acciones. Ese mismo d铆a vendi贸 40,000 acciones ordinarias a $62.00, reduciendo su tenencia directa a 138,641 acciones.
El expediente tambi茅n muestra una participaci贸n beneficiaria indirecta de 208,570 acciones en The Peetz Family Trust y que las opciones ejercidas est谩n totalmente consolidadas. Todas las transacciones informadas se realizaron bajo un plan escrito 10b5-1 adoptado el 22 de noviembre de 2024.
Christopher Peetz電� Mirum Pharmaceuticals鞚� CEO 瓴� 鞚挫偓搿滌劀 08/11/2025鞐� Rule 10b5-1 瓿勴殟鞐� 霐半澕 甏�霠� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽姅 歆侅洂 鞀ろ啞鞓奠厴 40,000欤茧ゼ 頄夓偓頄堨溂氅� 頄夓偓 臧�瓴╈潃 $2.936鞓�瓿�, 攴� 瓴瓣臣 歆侅爲 氤挫湢頃� 氤错喌欤缄皜 178,641欤�搿� 歃濌皜頄堨姷雼堧嫟. 臧欖潃 雮� 攴鸽姅 氤错喌欤� 40,000欤茧ゼ 欤茧嫻 $62.00鞐� 毵り皝頃橃棳 歆侅爲 氤挫湢霟夓澊 138,641欤�搿� 臧愳唽頄堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 The Peetz Family Trust臧� 氤挫湢頃� 臧勳爲鞝� 鞁れ 靻岇湢 208,570欤�鞕� 頄夓偓霅� 鞓奠厴鞚� 鞕勳爠頌� 氩犾姢韺呺悩鞐堨潓鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 氇摖 瓯半灅電� 2024雲� 11鞗� 22鞚� 毂勴儩霅� 靹滊┐ 10b5-1 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Christopher Peetz, PDG et administrateur de Mirum Pharmaceuticals, a d茅clar茅 des op茅rations li茅es en date du 08/11/2025 ex茅cut茅es en vertu d鈥檜n plan Rule 10b5-1. Il a exerc茅 40,000 options d鈥檃chat pour salari茅s au prix d鈥檈xercice de $2.936, portant ses actions ordinaires d茅tenues directement 脿 178,641 titres. Le m锚me jour, il a vendu 40,000 actions ordinaires 脿 $62.00, r茅duisant sa participation directe 脿 138,641 titres.
Le d茅p么t indique 茅galement une participation b茅n茅ficiaire indirecte de 208,570 actions d茅tenue par The Peetz Family Trust et pr茅cise que les options exerc茅es sont enti猫rement acquises. Toutes les op茅rations signal茅es ont 茅t茅 r茅alis茅es dans le cadre d鈥檜n plan 茅crit 10b5-1 adopt茅 le 22 novembre 2024.
Christopher Peetz, CEO und Direktor von Mirum Pharmaceuticals, meldete am 08.11.2025 Transaktionen im Zusammenhang mit einem Rule-10b5-1-Plan. Er 眉bte 40,000 Mitarbeiteraktienoptionen aus zum Aus眉bungspreis von $2.936, wodurch sein direkt gehaltener Stammaktienbestand auf 178,641 Aktien anstieg. Am selben Tag verkaufte er 40,000 Stammaktien zu $62.00 und verringerte damit seinen Direktbestand auf 138,641 Aktien.
Die Meldung weist zudem eine indirekte wirtschaftliche Beteiligung von 208,570 Aktien der Peetz Family Trust aus und best盲tigt, dass die ausge眉bten Optionen vollst盲ndig unverfallbar sind. Alle gemeldeten Transaktionen erfolgten im Rahmen eines schriftlichen 10b5-1-Plans, der am 22. November 2024 verabschiedet wurde.
- Transactions executed under a Rule 10b5-1 plan, indicating pre-planned trades and reduced insider trading risk
- Exercise of fully vested employee stock options, converting options into common shares
- Substantial indirect ownership remains (208,570 shares held by The Peetz Family Trust), maintaining economic alignment
- Sale of 40,000 shares at $62.00 reduced direct ownership from 178,641 to 138,641 shares
- Large insider sale could be perceived negatively by some investors, though it was pre-planned
Insights
TL;DR: Insider transactions were pre-planned under a 10b5-1 plan and include an option exercise and an equal-sized block sale.
The transactions are explicitly reported as made pursuant to a Rule 10b5-1 trading plan, which indicates the trades were pre-scheduled and intended to provide an affirmative defense against insider trading claims. The CEO converted 40,000 vested options at a low exercise price ($2.936) and simultaneously sold 40,000 shares at $62.00. From a governance perspective, the use of a 10b5-1 plan reduces regulatory risk, while the sale materially reduces the CEO's direct share count by 40,000 shares. The presence of significant indirect ownership via a family trust (208,570 shares) suggests continued economic exposure.
TL;DR: Transaction structure is neutral; option exercise funded or converted into sale proceeds, with sustained indirect ownership.
The report shows an exercise of employee stock options that were fully vested and the subsequent sale of the same number of shares. The exercise price of $2.936 versus the sale price of $62.00 highlights a large realized spread per share, but the filing contains no information about the use of proceeds or market impact. After the transactions, direct holdings moved from 178,641 to 138,641 shares, while indirect holdings remain 208,570. On materiality, these are routine, pre-planned insider transactions rather than an unplanned, material governance event.
Christopher Peetz, CEO e membro del consiglio di Mirum Pharmaceuticals, ha segnalato operazioni correlate in data 08/11/2025 eseguite ai sensi di un piano Rule 10b5-1. Ha esercitato 40,000 opzioni azionarie per dipendenti con prezzo di esercizio di $2.936, portando la sua partecipazione diretta in azioni ordinarie a 178,641 azioni. Nella stessa data ha venduto 40,000 azioni ordinarie a $62.00, riducendo la sua detenzione diretta a 138,641 azioni.
Il deposito indica inoltre una detenzione beneficiaria indiretta di 208,570 azioni tramite The Peetz Family Trust e specifica che le opzioni esercitate sono pienamente vestite. Tutte le operazioni segnalate sono state effettuate nell'ambito di un piano scritto 10b5-1 adottato il 22 novembre 2024.
Christopher Peetz, CEO y director de Mirum Pharmaceuticals, inform贸 transacciones relacionadas el 08/11/2025 ejecutadas conforme a un plan Rule 10b5-1. Ejerci贸 40,000 opciones sobre acciones para empleados con un precio de ejercicio de $2.936, lo que elev贸 su participaci贸n directa en acciones ordinarias a 178,641 acciones. Ese mismo d铆a vendi贸 40,000 acciones ordinarias a $62.00, reduciendo su tenencia directa a 138,641 acciones.
El expediente tambi茅n muestra una participaci贸n beneficiaria indirecta de 208,570 acciones en The Peetz Family Trust y que las opciones ejercidas est谩n totalmente consolidadas. Todas las transacciones informadas se realizaron bajo un plan escrito 10b5-1 adoptado el 22 de noviembre de 2024.
Christopher Peetz電� Mirum Pharmaceuticals鞚� CEO 瓴� 鞚挫偓搿滌劀 08/11/2025鞐� Rule 10b5-1 瓿勴殟鞐� 霐半澕 甏�霠� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽姅 歆侅洂 鞀ろ啞鞓奠厴 40,000欤茧ゼ 頄夓偓頄堨溂氅� 頄夓偓 臧�瓴╈潃 $2.936鞓�瓿�, 攴� 瓴瓣臣 歆侅爲 氤挫湢頃� 氤错喌欤缄皜 178,641欤�搿� 歃濌皜頄堨姷雼堧嫟. 臧欖潃 雮� 攴鸽姅 氤错喌欤� 40,000欤茧ゼ 欤茧嫻 $62.00鞐� 毵り皝頃橃棳 歆侅爲 氤挫湢霟夓澊 138,641欤�搿� 臧愳唽頄堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 The Peetz Family Trust臧� 氤挫湢頃� 臧勳爲鞝� 鞁れ 靻岇湢 208,570欤�鞕� 頄夓偓霅� 鞓奠厴鞚� 鞕勳爠頌� 氩犾姢韺呺悩鞐堨潓鞚� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 氇摖 瓯半灅電� 2024雲� 11鞗� 22鞚� 毂勴儩霅� 靹滊┐ 10b5-1 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Christopher Peetz, PDG et administrateur de Mirum Pharmaceuticals, a d茅clar茅 des op茅rations li茅es en date du 08/11/2025 ex茅cut茅es en vertu d鈥檜n plan Rule 10b5-1. Il a exerc茅 40,000 options d鈥檃chat pour salari茅s au prix d鈥檈xercice de $2.936, portant ses actions ordinaires d茅tenues directement 脿 178,641 titres. Le m锚me jour, il a vendu 40,000 actions ordinaires 脿 $62.00, r茅duisant sa participation directe 脿 138,641 titres.
Le d茅p么t indique 茅galement une participation b茅n茅ficiaire indirecte de 208,570 actions d茅tenue par The Peetz Family Trust et pr茅cise que les options exerc茅es sont enti猫rement acquises. Toutes les op茅rations signal茅es ont 茅t茅 r茅alis茅es dans le cadre d鈥檜n plan 茅crit 10b5-1 adopt茅 le 22 novembre 2024.
Christopher Peetz, CEO und Direktor von Mirum Pharmaceuticals, meldete am 08.11.2025 Transaktionen im Zusammenhang mit einem Rule-10b5-1-Plan. Er 眉bte 40,000 Mitarbeiteraktienoptionen aus zum Aus眉bungspreis von $2.936, wodurch sein direkt gehaltener Stammaktienbestand auf 178,641 Aktien anstieg. Am selben Tag verkaufte er 40,000 Stammaktien zu $62.00 und verringerte damit seinen Direktbestand auf 138,641 Aktien.
Die Meldung weist zudem eine indirekte wirtschaftliche Beteiligung von 208,570 Aktien der Peetz Family Trust aus und best盲tigt, dass die ausge眉bten Optionen vollst盲ndig unverfallbar sind. Alle gemeldeten Transaktionen erfolgten im Rahmen eines schriftlichen 10b5-1-Plans, der am 22. November 2024 verabschiedet wurde.
FAQ
What insider transactions did Mirum (MIRM) report for CEO Christopher Peetz?
Were these trades part of a pre-arranged plan for MIRM insider Christopher Peetz?
How many Mirum shares does Christopher Peetz beneficially own after these transactions?
Were the stock options exercised by Christopher Peetz vested?
Does the Form 4 indicate why the shares were sold?
